Stephens Cuts OptimizeRx (NASDAQ:OPRX) Price Target to $17.00

OptimizeRx (NASDAQ:OPRX) had its price target decreased by Stephens from $20.00 to $17.00 in a research report released on Monday,Benzinga reports. Stephens currently has an equal weight rating on the stock.

Other analysts have also issued research reports about the company. Roth Capital reissued a “buy” rating on shares of OptimizeRx in a report on Friday, August 8th. Zacks Research downgraded OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. Wall Street Zen raised shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. UBS Group set a $23.00 price target on shares of OptimizeRx in a report on Friday, October 10th. Finally, Stifel Nicolaus upped their price target on shares of OptimizeRx from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.88.

OptimizeRx Stock Up 1.0%

Shares of OPRX stock opened at $14.26 on Monday. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.21. OptimizeRx has a 12 month low of $3.99 and a 12 month high of $22.25. The stock has a market cap of $265.82 million, a P/E ratio of -26.41 and a beta of 1.24. The company has a 50 day simple moving average of $18.45 and a two-hundred day simple moving average of $15.50.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.17. The business had revenue of $26.07 million for the quarter, compared to analysts’ expectations of $23.83 million. OptimizeRx had a negative net margin of 9.42% and a positive return on equity of 4.50%. OptimizeRx has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts expect that OptimizeRx will post -0.33 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Patrick D. Spangler sold 11,120 shares of the business’s stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $17.49, for a total value of $194,488.80. Following the transaction, the director owned 44,215 shares of the company’s stock, valued at approximately $773,320.35. The trade was a 20.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Stephen L. Silvestro sold 1,620 shares of the company’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $18.75, for a total transaction of $30,375.00. Following the transaction, the chief executive officer owned 188,916 shares of the company’s stock, valued at approximately $3,542,175. This represents a 0.85% decrease in their position. The SEC filing for this sale provides additional information. 5.60% of the stock is currently owned by insiders.

Institutional Trading of OptimizeRx

Several hedge funds have recently bought and sold shares of OPRX. Bank of New York Mellon Corp boosted its holdings in shares of OptimizeRx by 2.1% during the 1st quarter. Bank of New York Mellon Corp now owns 89,538 shares of the company’s stock valued at $775,000 after purchasing an additional 1,826 shares during the last quarter. Blair William & Co. IL lifted its position in shares of OptimizeRx by 4.9% in the first quarter. Blair William & Co. IL now owns 631,031 shares of the company’s stock worth $5,465,000 after buying an additional 29,648 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in OptimizeRx by 30.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 54,228 shares of the company’s stock valued at $470,000 after buying an additional 12,676 shares during the last quarter. Invesco Ltd. purchased a new position in OptimizeRx during the 1st quarter valued at approximately $2,542,000. Finally, Virtu Financial LLC bought a new stake in OptimizeRx in the 1st quarter worth approximately $112,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.